Vancomycin-resistant enterococci.

摘要: Over the last 2 decades, enterococci, formerly viewed as organisms of minimal clinical impact, have emerged important hospital-acquired pathogens in immunosuppressed patients and intensive care units (ICUs). Vancomycin resistance enterococci is increasing steadily. Vancomycin-resistant (VRE) composed 26% nosocomial 1999, a 47% increase from 1994 to 1998. More that 25% ICU are resistant vancomycin. Antimicrobial therapy problematic for all VRE, but particularly when bactericidal activity necessary. Quinipristin-dalfopristin linezolid new approved antimicrobials treatment recalcitrant infections caused byVRE. Control transmission although successful preventing infections, neither simple nor inexpensive, VRE has become endemic many hospitals. However, endemicity poses serious risks health current future patients, itself, expensive. Data on cost-effectiveness prevention programs currently lacking urgently needed; however, because added cost single infection far exceeds those gowns, gloves, screening, it seems likely such control represent significant savings hospitals willing undertake them.